PFE Pfizer Inc
Company Analysis
Latest News
Pfizer Teams With Enodia on Sec61 Inhibitors in Potential $500M-Plus Deal
Pfizer has entered into a research collaboration and licensing agreement with Enodia Therapeutics to discover and develop Sec61 inhibitors. The deal could be...
Pfizer to Present 50+ Abstracts at IDWeek 2026, Including Late-Breaking Data
Pfizer Inc. will present data from more than 50 abstracts at IDWeek 2026 in Washington, D.C. The presentations include 12 oral sessions covering the company’s...
Pfizer Wins FDA Approval for TUKYSA in HER2-Positive Breast Cancer
Pfizer Inc. announced on October 7, 2026, that the U.S. Food and Drug Administration (FDA) approved TUKYSA, in combination with trastuzumab and pertuzumab, for...
Pfizer to Cut 330 Jobs at Sicily Plant After Failed Talks
Pfizer plans to cut around 330 jobs at its plant in Sicily, according to labor unions. The move follows unsuccessful negotiations between the pharmaceutical...
Pfizer Presents Durable Survival Data for Bladder Cancer Combo at ESMO
Pfizer and Astellas presented new data at the European Society for Medical Oncology (ESMO) 2026 congress on PADCEV (enfortumab vedotin) plus pembrolizumab for...
Pfizer Faces Florida Suit Over COVID-19 Vaccine Safety and Effectiveness Claims
Florida Attorney General James Uthmeier filed a lawsuit on Thursday against Pfizer and CEO Albert Bourla, accusing the company of misleading the public about...
Pfizer and Moderna Must Face Bayer's mRNA Patent Lawsuit
A federal judge in Delaware denied requests from Pfizer, BioNTech, and Moderna. These companies sought to dismiss a patent infringement lawsuit. Bayer filed...
BridgeBio’s Attruby Beats Pfizer’s Vyndamax, Reducing Clinical Risks by 34%
BridgeBio Pharma’s Attruby outperformed Pfizer’s Vyndamax in a real-world study of transthyretin amyloid cardiomyopathy (ATTR-CM) patients. The peer-reviewed...
Pfizer pivots to oncology and vaccines, targeting $4 billion in new revenue
Pfizer Chief International Commercial Officer Alexandre de Germay detailed a strategic shift away from COVID-19 products at the J.P. Morgan U.S. All Stars...
Pfizer to Share Revenue From Higher Overseas Drug Prices With U.S. Government
Pfizer will share a portion of revenue with the U.S. Department of Health and Human Services (HHS). This applies if the company charges higher prices for its...
Pfizer freezes dividend until 2028, citing falling COVID-19 drug revenue
Pfizer has ended its 15-year streak of annual dividend increases. The company maintained its quarterly payout at $0.43 per share in January 2026. This decision...
US Government Probes Alleged Link Between COVID-19 Vaccines and Military Deaths
The U.S. Departments of Health and Human Services (HHS) and Defense are investigating a potential link between COVID-19 vaccines, including Pfizer's, and...
Pfizer Licenses Oncology Drug to Medicus Pharma in Deal Worth Over $1B
Pfizer has granted Medicus Pharma an exclusive worldwide license to co-develop and commercialize its early-stage antibody-drug conjugate (ADC), PF-08046031....
Pfizer-Backed Priovant Wins FDA Approval for Autoimmune Drug Lisraya
Priovant Therapeutics, formed by Roivant Sciences and Pfizer, received FDA approval for Lisraya (brepocitinib). The drug treats adults with dermatomyositis....
Pfizer Secures FDA Approval for 2026-2027 COVID Shot, Targeting XFG Variant
Pfizer and BioNTech secured FDA approval for their updated 2026-2027 COVID-19 vaccine. The new formula targets the XFG variant to align with current viral...
OrbiMed Advisors Exits Pfizer Stake, Sells 1.95M Shares
Healthcare-focused investment firm OrbiMed Advisors completely sold off its stake in Pfizer (PFE), according to a quarterly disclosure filed on August 14,...
Pfizer Rallies 11%, Driven by Renewed mRNA Cancer Vaccine Optimism
Pfizer shares climbed 11.43% over the past 30 days as investors reassess the company’s mRNA oncology pipeline. This momentum follows positive Phase 3 results...
Steve Cohen's Point72 Exits $122M Pfizer Position
In a significant portfolio change, Point72, the investment firm led by Steve Cohen, liquidated its entire stake in Pfizer (PFE). The firm sold all 4.37 million...
Pfizer launches Depo-Provera settlement, addressing $1.2 billion in brain tumor claims
Pfizer established a settlement program to resolve federal lawsuits involving its Depo-Provera birth control shot. Plaintiffs allege the injection caused...
Pfizer and Valneva's Lyme Vaccine Application Advances to EMA Review
Pfizer and Valneva announced the European Medicines Agency (EMA) validated their Marketing Authorization Application for VLA15, an investigational Lyme disease...